Get started
Author

Luca Cancanelli

Observed names: Cancanelli, Luca, L Cancanelli
Observed institutions: University of Padua, University of Milan, Ospedale Santa Chiara, AULSS 2 Marca Trevigiana, Ospedale di Mirano, Azienda Ospedale - Università Padova, Regione Toscana
ORCID: 0000-0002-6409-4195
Observed ORCID: 0000-0002-6409-4195
OpenAlex ID: A5035062141
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
2020 · Francesco Perrone, Maria Carmela Piccirillo, et al. · Journal of Translational Medicine · 144
PDF
Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses
2023 · Andrea Messori, Vera Damuzzo, et al. · Cancers · 24
PDF
Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials
2021 · Luca Cancanelli, Melania Rivano, et al. · Cureus · 13
PDF
The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
2022 · Lorenzo Di Spazio, Melania Rivano, et al. · Cureus · 9
PDF
A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia
2021 · Andrea Messori, Melania Rivano, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 8
Comparative Analysis of Maintenance Treatments in Patients with Newly Diagnosed Advanced Ovarian Cancer After First-Line Platinum-Based Regimens
2025 · Lorenzo Gasperoni, Luca Cancanelli, et al. · Cancers · 5
PDF
The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma
2022 · Andrea Messori, Melania Rivano, et al. · Cureus · 5
PDF
Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
2021 · L Di Spazio, L Cancanelli, et al. · PubMed · 5
Restricted Mean Survival Time as Outcome Measure in Advanced Urothelial Bladder Cancer: Analysis of 4 Clinical Studies
2020 · Melania Rivano, Luca Cancanelli, et al. · Immunotherapy · 5
Radiofrequency or cryoablation or medical therapy for paroxysmal atrial fibrillation: An indirect comparison of effectiveness
2025 · Roberto Brunoro, Lorenzo Di Spazio, et al. · Journal of Arrhythmia · 4
PDF
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy
2022 · Daniele Mengato, Luca Cancanelli, et al. · International Journal of Clinical Pharmacology and Therapeutics · 4
Radiofrequency Ablation, Cryotherapy Ablation, or Pulsed-Field Ablation to Treat Paroxysmal Atrial Fibrillation Unresponsive to Pharmacological Treatments: Interpreting Efficacy Through Reconstruction of Individual Patient Data From Randomized Trials
2024 · Melania Rivano, Luca Cancanelli, et al. · Cureus · 3
PDF
Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
2023 · Luca Cancanelli, Melania Rivano, et al. · Hematology Reports · 3
PDF
First-Line Chemoimmunotherapy Versus Chemotherapy in PD-L1-Negative Patients with Non-Small-Cell Lung Cancer
2022 · Daniele Mengato, Luca Cancanelli, et al. · Immunotherapy · 3
Applicazione dell’intelligenza artificiale per un precoce confronto di efficacia tra nuovi farmaci oncologici
2022 · Vera Damuzzo, Melania Rivano, et al. · Recenti Progressi in Medicina · 2
PDF
Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials
2022 · Melania Rivano, Luca Cancanelli, et al. · World Journal of Urology · 2
Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy
2021 · Luca Cancanelli, Daniele Mengato, et al. · International Journal of Clinical Pharmacology and Therapeutics · 2
3PC-019 In use physicochemical and microbiological stability of diluted solutions of the monoclonal antibody nivolumab
2020 · M Rivano, F Selmin, et al. · European Journal of Hospital Pharmacy · 2
PDF
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
2021 · Francesco Perrone, Maria Carmela Piccirillo, et al. · Journal of Translational Medicine · 1
PDF
Experience in managing independent clinical research, the best training strategy for future clinical pharmacists: the QOSMOS project
2021 · Vera Damuzzo, Laura Agnoletto, et al. · European Journal of Hospital Pharmacy · 1
3PC-044 In use physicochemical stability of pembrolizumab under the dilution condition required for use in a day hospital
2020 · M Piccoli, F Selmin, et al. · European Journal of Hospital Pharmacy · 1
PDF
3PC-015 Short term stability of diluted solutions of the monoclonal antibody daratumumab
2020 · G Mangoni, F Selmin, et al. · European Journal of Hospital Pharmacy · 1
PDF
Heterogeneity of the Italian residency training in hospital pharmacy: a pilot study from students’ perspective
2018 · Vera Damuzzo, Roberto Langella, et al. · Padua Research Archive (University of Padova) · 1
Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
2026 · Luna Del Bono, Andrea Ossato, et al. · Frontiers in Oncology
PDF
Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
2026 · Luna Del Bono, Andrea Ossato, et al. · Frontiers in Oncology
Works count: 34
Citation count: 248
H-index: 5
I10-index: 3
Year
Topic
Type